Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

This study is comparing two treatments for advanced liver cancer (hepatocellular carcinoma, or HCC) that has already progressed after a combination of anti-PD-1/PD-L1 immunotherapy and bevacizumab: lenvatinib plus tislelizumab (an additional immunotherapy added back in) versus lenvatinib alone (a targeted therapy tablet). **You may be eligible if...** - You are 18 or older with confirmed advanced liver cancer (HCC) - Your cancer progressed after treatment with anti-PD-1/PD-L1 and bevacizumab - You have measurable disease on imaging - Your liver function score (Child-Pugh) is 5–7, and your performance status (ECOG) is 2 or lower - Your blood counts, liver enzymes, and kidney function are adequate - If you have chronic hepatitis B, your viral load is controlled with antiviral therapy **You may NOT be eligible if...** - You have rare liver cancer subtypes (fibrolamellar, sarcomatoid, or mixed cholangiocarcinoma) - You are on a liver transplant waiting list - You had a stroke, blood clot, or significant gastrointestinal bleeding recently - You are immunocompromised (e.g., HIV positive) - You have another active cancer Talk to your doctor to see if this trial is right for you.